help button home button Endocrine Society JCEM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Full Text (PDF)
Right arrow Submit a related Letter to the Editor
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Yamada, S.
Right arrow Articles by Shishiba, Y.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Yamada, S.
Right arrow Articles by Shishiba, Y.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH

Journal of Clinical Endocrinology & Metabolism, Vol 76, 352-356, Copyright © 1993 by Endocrine Society

ARTICLES

Endocrine and morphological study of a clinically silent somatotroph adenoma of the human pituitary

S Yamada, T Sano, L Stefaneanu, K Kovacs, T Aiba, S Sawano and Y Shishiba
Department of Neurosurgery, Toranomon Hospital, Tokyo, Japan.

Silent somatotroph adenomas are defined as tumors showing morphological features consistent with GH production, but no clinical evidence of GH excess. We report here the case of a 46-yr-old woman with a large pituitary macroadenoma, slightly elevated serum GH levels, high serum insulin-like growth factor-I levels, and abnormal GH dynamics, but no acromegaly. The endocrinological abnormalities receded after transphenoidal surgery despite tumor persistence, as shown by neuroimaging. The reverse hemolytic plaque assay, performed for the first time in a silent GH cell adenoma, demonstrated that the number of GH cells releasing GH and the amount of GH discharged from individual cells were less than those in clinically functioning somatotroph adenomas. Thus, it is conceivable that this tumor secreted only small quantities of GH and for only short periods, providing an explanation for the lack of acromegaly. It appears that silent somatotroph adenomas do not represent a distinct entity. It is more likely that there is a continuous spectrum from clinically functioning, sparsely granulated somatotroph adenomas with high serum GH levels to silent somatotroph adenomas with normal serum GH levels. The cause of the lack of GH oversecretion in silent GH cell adenomas has yet to be elucidated.


This article has been cited by other articles:


Home page
 J. Clin. Endocrinol. Metab.Home page
A. A. Sakharova, E. V. Dimaraki, W. F. Chandler, and A. L. Barkan
Clinically Silent Somatotropinomas May Be Biochemically Active
J. Clin. Endocrinol. Metab., April 1, 2005; 90(4): 2117 - 2121.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
A. Barlier, I. Pellegrini-Bouiller, G. Gunz, A. J. Zamora, P. Jaquet, and A. Enjalbert
Impact of gsp Oncogene on the Expression of Genes Coding for Gs{alpha}, Pit-1, Gi2{alpha}, and Somatostatin Receptor 2 in Human Somatotroph Adenomas: Involvement in Octreotide Sensitivity
J. Clin. Endocrinol. Metab., August 1, 1999; 84(8): 2759 - 2765.
[Abstract] [Full Text]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 1993 by The Endocrine Society